Announcements Trials

Browse Landscape Eligibility

Clinical Trials

0 trials

Recent Start date Enrollment

Primary Myelofibrosis × darolutamide × 90 days × Clear all

Sponsor

Conditions

Prostatic Neoplasms 25 Urogenital Neoplasms 2 Prostatic Neoplasms, Castration-Resistant 2 Neoplasm Metastasis 2 Biochemically Recurrent Prostate Cancer 2 Adenocarcinoma 2 Urogenital Diseases 1 Prostatic Diseases 1 Prostate Adenocarcinoma 1 Non-metastatic Castration-resistant Prostate Cancer 1 Neoplasms by Site 1 Neoplasms 1 Metastatic Castration-resistant Prostate Neoplasms 1 Metastatic Castration-resistant Prostate Cancer 1 Male Urogenital Diseases 1 High-Risk Localized Prostate Cancer 1 Granulosa cell tumor of the ovary 1 Carcinoma, Transitional Cell 1 Carcinoma, Renal Cell 1 Bulbo-Spinal Atrophy, X-Linked 1

Interventions

ruxolitinib 8 fludarabine 4 Tacrolimus 4 Cyclophosphamide 4 Whole-Body Irradiation 3 Stem Cell Transplantation 3 Specimen Handling 3 venetoclax 2 fludarabine phosphate 2 Mycophenolic Acid 2 Melphalan 2 Decitabine 2 Busulfan 2 Biopsy 2 Azacitidine 2 11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 2 veliparib 1 selinexor 1 reparixin 1 piperine 1 pevonedistat 1 navitoclax 1 merphos 1 iadademstat 1 fedratinib 1 elotuzumab 1 demethoxycurcumin 1 decitabine and cedazuridine drug combination 1 bomedemstat 1 axatilimab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

No trials found.

Data powered by HemOnc (CC BY 4.0) Colophon ⚡